Skip to main content
SpringerLink
Log in
Book cover

Hematopoietic Growth Factors in Oncology pp 311–332Cite as

Role of Cytokines in the Management of Chronic Lymphocytic Leukemia

  • Chapter

  • 161 Accesses

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults in Western countries. The annual incidence estimate from the American Cancer Society is for approx 7000 new cases in the United States in 2003. (This number suggests an apparent decline in incidence, but it may reflect an increased ability to distinguish CLL from other chronic lymphoid leukemias [1].) CLL tends to be a disease of the elderly; the median age at diagnosis is 62 yr, and only 15% of patients present at an age younger than 50 yr (2).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Cancer Society Cancer Facts and Figures 2002;5.

    Google Scholar 

  2. Ries LAG, Miller BA, Hankey BF, et al. Surveillance Epidemiology End Results (SEER) Cancer Statistics Review 1973–1991: Tables and Graphics. Report no: NIH-94–2789. Bethesda, MD: National Cancer Institute. 1994.

    Google Scholar 

  3. Freedman AS, Nadler LM. Immunologic markers in B cell chronic lymphocytic leukemia. In: Cheson BD, ed., Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments, 2nd ed. Dekker, New York, NY, 2001.

    Google Scholar 

  4. Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 1997; 158: 235–246.

    PubMed  CAS  Google Scholar 

  5. Manison YA. The infectious complication of chronic lymphocytic leukemia. Semin Oncol 1998; 25: 98–106.

    Google Scholar 

  6. Heath ME, Cheson BD. Defective complement activation in chronic lymphocytic leukemia. Am J Hematol 1985; 19: 63–73.

    Article  PubMed  CAS  Google Scholar 

  7. Bunch C, Chapel H, Gale RP. Infection complications in CLL. In: Polliack A, Cotouskey D, eds., Chronic Lymphocytic Leukemia. London: Harwood Academic. 1988: 248–262.

    Google Scholar 

  8. Cooperative Group for the Study of Immunoglobulins in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 1988; 319: 902–907.

    Google Scholar 

  9. Kalil N, Cheson BD. Management of chronic lymphocytic leukemia. Drugs Aging 2000; 16: 9–27.

    Article  PubMed  CAS  Google Scholar 

  10. Duhrsen U, Augener W, Zwingers T, et al. Spectrum and frequency of auto immune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 1987; 67: 235–239.

    Article  PubMed  CAS  Google Scholar 

  11. Ritch PS, Anderson T. Reversal of autoimmune hemolytic anemia associated with chronic lymphocytic leukemia following high dose immunoglobulin. Cancer 1987; 60: 2637–2640.

    Article  PubMed  CAS  Google Scholar 

  12. Binet J, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206.

    Article  PubMed  CAS  Google Scholar 

  13. Rozman C, Montserrat E, Rodriguez-Fernandez JM, et al. Bone marrow histologic pattern-the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 1984; 64: 642–648.

    PubMed  CAS  Google Scholar 

  14. Pangalis GA, Angelopoulou MK, Vassilakopoulos TP, et al. B-chronic lymphocytic leukemia, small lymphocyte lymphoma and lymphocytic leukemia, lymphoplasmacytic lymphoma including Walden-ström’s macroglobulinemia: a clinical, morphologic and biologic spectrum of similar disorders. Semin Hematol 1999; 36: 104–114.

    PubMed  CAS  Google Scholar 

  15. Means RT, Krantz SB. Progress in understanding the parthogenesis of the anemia of chronic disease. Blood 1992; 80: 1639–1642.

    PubMed  Google Scholar 

  16. Sears DA. Anemia of chronic disease. Med Clin North Am 1992; 76: 567–579.

    PubMed  CAS  Google Scholar 

  17. Faquin WC, Schneider Ti, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1994; 79: 1987–1994.

    Google Scholar 

  18. Hulkkonen J, Vilpo J, et al. Interleukin/B, interleukin-1 receptor antagonist and interleukin 6 plasma levels and cytokine gene polymorphisms in chronic lymphocytic leukemia: cancellation with prognostic parameters. Haematologica 2000; 85: 600–606.

    PubMed  CAS  Google Scholar 

  19. Beguin Y, Lampertz S, Bron D, et al. Serum erythropoiesis in chronic lymphocytic leukemia. Br J Haematol 1996; 93: 154–156.

    Article  PubMed  CAS  Google Scholar 

  20. Chikkappa G, Pasquale D, Zarrabi MH, et al. Cyclosporine and prednisone therapy for pure red cell aplasia in patients with chronic lymphocytic leukemia. Am J Hematol 1992; 41: 5–12.

    Article  PubMed  CAS  Google Scholar 

  21. Kohlman A, Schoh C, Dugas M, et al. Gene expression profiles of distinct cytogenetic CCL subtypes. Blood 2002: 100: 168a (abstract 169).

    Google Scholar 

  22. Cheson BD, Bennet JM, Greyer M, et al. National Cancer Institute Working Group guideline for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996: 87: 4990–4997.

    PubMed  CAS  Google Scholar 

  23. French Cooperative Group on CLL, Johnson S, Smith AG, et al. Randomized trial of fludarabine versus cyclophosphamide, doxorubicin and prednisone for treatment of advanced stage chronic lymphocytic leukemia. Lancet 1996; 347: 1432–1437.

    Google Scholar 

  24. Rai KR, Peterson B, Elias L, et al. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CT C/NCl-C and ECOG Intergroup Study. Blood 1996; 88: 141a (abstract 552).

    Google Scholar 

  25. Leporrier S, Chevret B, Cazin B, et al. Randomized comparison of fludarabine CAO and CHOP in 695 previously untreated stage B and C chronic lymphocytic leukemia (CLL): early stopping of the CAP accrual. Blood 1997; 90: 5290a (abstract 2357).

    Google Scholar 

  26. Bowen AL, Zomas A, Emmett E, et al. Subcutaneous CAMPATH-1H in fludarabine resistant/relapsed chronic lymphocytic and B-prolymphocytic leukemia. Br J Haematol 1997; 96: 617–619.

    Article  PubMed  CAS  Google Scholar 

  27. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response. Blood 1995; 86: 4446–4453.

    PubMed  CAS  Google Scholar 

  28. Österborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemia patients with multiple myeloma and non-Hodgkin’s lymphoma: a randomized multicenter study-The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. Blood 1996; 87: 2675–2682.

    PubMed  Google Scholar 

  29. Österborg A, Brandberg Y, Molostova V, et al. Randomized, double blind, placebo controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002; 20: 2486–2494.

    Article  PubMed  Google Scholar 

  30. Rose E, Rai K, Revicki D, et al. Clinical and health status assessments in anemia chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO). Blood 1994; 8: 256 (abstract 2091).

    Google Scholar 

  31. Hedenus M, Hansen S, Taylor K, et al. Randomized dose finding study of darbepoetin alfa in anemic patients with lymphoproliferative malignancies. Br J Haematol 2002; 119: 79–86.

    Article  PubMed  CAS  Google Scholar 

  32. Pangalis GA, Poziopoulos C, Angelopoulou M, et al. Effective treatment of disease-related anemia in B-chronic lymphocytic leukemia patients with recombinant human erythropoietin. Br J Haematol 1995; 89: 627–629.

    Article  PubMed  CAS  Google Scholar 

  33. Siakantaris M, Angelopoulou M, Vassilakopoulos TP, et al. Correction of disease-related anemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: maintenance is necessary to sustain response. Leuk Lymphoma 2000; 40: 141–147.

    Article  PubMed  CAS  Google Scholar 

  34. Pangalis GA, Siakantaris MP, Angelopoulou MK, et al. Downstaging Rai stage III B-chronic lymphocytic leukemia patients with the administration of recombinant human erythropoietin. Haematologica 2002; 87: 500–506.

    PubMed  CAS  Google Scholar 

  35. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20: 4083–4107.

    Article  PubMed  CAS  Google Scholar 

  36. Ludwig H, Rai K, Blade J, et al. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J 2002; 3: 121–130.

    Article  PubMed  CAS  Google Scholar 

  37. O’Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis derived prognostic model for response to treatment. Blood 1993; 82: 1695–1700.

    PubMed  Google Scholar 

  38. O’Brien S, Kantarjian H, Beran M, et al. Fludarabine and granulocyte colony stimulating factor (GCSF) in patients with chronic lymphocytic leukemia. Leukemia 1997; 11: 1631–1635.

    Article  PubMed  Google Scholar 

  39. DeNully Brown P, Hansen M. GMCSF treatment in patients with B-chronic lymphocytic leukemia. Leuk Lymphoma 1999; 32: 365–368.

    CAS  Google Scholar 

  40. Itala M, Pelliniemi T-T, Remes K, et al. Long term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenia infections. Leuk Lymphoma 1998; 32: 165–174.

    PubMed  CAS  Google Scholar 

  41. Vadhan-Raj S, Velasquez W, Butler J, et al. Stimulation of myelopoiesis in chronic lymphocytic leukemia and other lymphoproliferatived isorders by recombinant human granulocyte-macrophage colony stimulating factor. Am J Hematol 1990; 33: 189–197.

    Article  PubMed  CAS  Google Scholar 

  42. Dreger P, Neuhoff N, Suttorp M, et al. Rapid engraftment of peripheral blood progenitor cell grafts purged with B cell specific monoclonal antibodies and immunogenic beads. Bone Marrow Transplant 1995; 16: 627–629.

    PubMed  CAS  Google Scholar 

  43. Schmitz N, Linch DC, Dregen P, et al. Randomized trial of filgrastim mobilized peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–357.

    Article  PubMed  CAS  Google Scholar 

  44. Rozman C, Montserat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052–1057.

    Article  PubMed  CAS  Google Scholar 

  45. Khouri I, Keating M, Vriesendorp H, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748–758.

    PubMed  CAS  Google Scholar 

  46. Provan D, Bartlett-Pandite L, Zwicky C. Eradication of polymesase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 1996; 88: 2228–2235.

    PubMed  CAS  Google Scholar 

  47. Dreger P, von Neuhoff N, Kase R, et al. Early stem cell transplantation for chronic lymphocytic leukemia: a chance for cure? Br J Cancer 1998; 77: 2291–2297.

    Article  PubMed  CAS  Google Scholar 

  48. Dreger P, Viehmann K, von Neuhoff, et al. A prospective study of positive/negative ex vivo B-cell depletion in patients with chronic lymphocytic leukemia. Exp Hematol 2000; 28: 1187–1196.

    Article  PubMed  CAS  Google Scholar 

  49. Perez-Simon JA, Caballero D, Diez-Campelo M, et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16: 1423–1431.

    Article  PubMed  CAS  Google Scholar 

  50. Kolb H, Schaltenberg A, Goldman J, et al. Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1985; 86: 2041–2050.

    Google Scholar 

  51. Rondon G, Biralt S, Huh Y, et al. Graft versus leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1996; 18: 669–672.

    PubMed  CAS  Google Scholar 

  52. Khouri IF, Keating MJ, Vriesendorp HM, et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 1994; 12: 748–758.

    PubMed  CAS  Google Scholar 

  53. Michallet M, Archimbaud E. Bandini G, et al. HLA-identical sibling bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG. Bone Marrow Transplant 1991; 7: 275–279.

    PubMed  CAS  Google Scholar 

  54. Rabinowe SN, Soiffer RJ, Gribben JG, et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1366–1376.

    PubMed  CAS  Google Scholar 

  55. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: harnessing graft versus leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

    PubMed  CAS  Google Scholar 

  56. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19–25.

    Google Scholar 

  57. O’Brien S, Kantarjian H, Berane M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695–1700.

    PubMed  Google Scholar 

  58. Khouri IF, Keating MI, Korbling M, et al. Transplant-lite: induction of graft versus malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824.

    PubMed  CAS  Google Scholar 

  59. Perez-Simon JA, Caballero Diez-Compelo, et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16: 1423–1431.

    Article  PubMed  CAS  Google Scholar 

  60. Physician’s Desk Reference 2002.

    Google Scholar 

  61. Ozer H, Armitage JO, Bennett CL, et al. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000; 18: 3558–3585.

    Google Scholar 

  62. Russo F, Guadagni R, Mattera G, et al. Combination of granulocyte-macrophage colony stimulating factor (GM-CSF) and erythropoietin (EPO) for the treatment of advanced non-responsive chronic lymphocytic leukemia. Eur J Haematol 1999; 63: 325–331.

    Article  PubMed  CAS  Google Scholar 

  63. Kipps TJ. Signal transduction pathways and mechanisms of apoptosis in CLL-B lymphocytes: their role in CLL pathogenesis. Hematol Cell Ther 1997; 39: S17 - S27.

    Article  PubMed  Google Scholar 

  64. Wu H, Klingmuller N, Besmer P, et al. Interaction of the erythropoietin and stem cell factor receptors. Nature 1995; 377: 242–246.

    Article  PubMed  CAS  Google Scholar 

  65. Zhang MY, Harhaj EW, Bell L, et al. Bcl-3 expression and nuclear translocation are induced by proliferating human erythroid precursors. Blood 1998; 92: 1225–1234.

    PubMed  CAS  Google Scholar 

  66. Ludwig H. Anemia of hematologic malignancies: what are the treatment options? Semin Oncol 2002; 29: 45–54.

    PubMed  CAS  Google Scholar 

  67. Maretta G, et al. Low dose fludarabine and cyclophosphamide in elderly patients with B cell chronic lymphocytic leukemia refractory to conventional therapy. Haematologica 2000; 85: 1268–1270.

    Google Scholar 

  68. Dabaja B, O’Brien S, Kantarjian H, et al. Franctionated cyclophosphamide, vincristine, liposomal daunobrubin (Daunoxome) and dexamethasone (Hyper CVXD) regimen in Richter’s syndrome. Leuk Lymphoma 2001; 42: 329–337.

    Article  PubMed  CAS  Google Scholar 

  69. Flinn I, Jemiai Y, Bennet J, et al. Fludarabine and cyclophosphamide achieves high complete response rate in patients with primarily untreated chronic lymphocytic leukemia ECOG 1997. Blood 2001; 98: 633a.

    Google Scholar 

  70. Flinn I, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000; 96: 71–75.

    PubMed  CAS  Google Scholar 

  71. Mauro F, Foa R, Meloni G, et al. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Haematologica 2002; 87: 926–933.

    PubMed  CAS  Google Scholar 

  72. Robak T, Blonski J, Kaznicki M, et al. Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 2002; 3: 244–250.

    Article  PubMed  CAS  Google Scholar 

  73. McCune S, Gockerman J, Moore L, et al. Alemtuzamab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma 2002; 43: 1007–1011.

    Article  PubMed  CAS  Google Scholar 

  74. Lundin J, Kimby E. Bjorkholm M, et al. Phase III trial of subcutaneous anti CD-52 monoclonal antibody alemtuzamab (Campath I-H) as first line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768–773.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Carol Ann Long PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Amgen, Australia, Pty. Ltd., Monash University, Victoria, Australia

    George Morstyn MBBS, PhD, FRACP

  2. Amgen Inc., Thousand Oaks, CA, USA

    MaryAnn Foote PhD

  3. Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Melbourne, Australia

    Graham J. Lieschke MBBS, PhD, FRACP

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Long, C.A. (2004). Role of Cytokines in the Management of Chronic Lymphocytic Leukemia. In: Morstyn, G., Foote, M., Lieschke, G.J. (eds) Hematopoietic Growth Factors in Oncology. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-747-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-747-5_16

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9847-9

  • Online ISBN: 978-1-59259-747-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation